GeoVax to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
(firmenpresse) - ATLANTA, GA -- (Marketwire) -- 09/04/12 -- GeoVax Labs, Inc. (OTCQB: GOVX) (OTCBB: GOVX), a biotechnology company developing vaccines to prevent and fight HIV/AIDS, announced it will be presenting at the Rodman & Renshaw 2012 Annual Global Investment Conference in New York City.
Robert McNally, Ph.D., President and CEO of GeoVax, will deliver the Company presentation to conference attendees on Monday, September 10 at 2:50 PM ET in the Starlight North room at the Waldorf-Astoria Hotel. Dr. McNally will be joined at the conference by Mark Reynolds, GeoVax CFO.
Dr. McNally said, "Presenting at the Rodman & Renshaw Global Investment Conference provides an exciting opportunity for us to highlight our growing investment potential and clinical progress making our HIV/AIDS vaccines the leading candidate for the Americas and Europe."
More than 300 public and private companies from around the world are registered to present in front of an audience of over 3,000 attendees. Newt Gingrich, 58th Speaker of the U.S. House of Representatives, will open the Conference as the Keynote Speaker on Monday, September 10. Conference registration details can be found at:
.
GeoVax's unique two-component vaccine, a recombinant DNA and a recombinant modified vaccinia Ankara (MVA), is designed to stimulate both anti-HIV T cell and anti-HIV antibody immune responses. GeoVax's DNA and MVA vaccines are used in a prime/boost protocol in which priming is done with the DNA and boosting with the MVA. Both the DNA and MVA express the three major proteins of the AIDS virus: Gag, Pol, and Env, and produce noninfectious virus-like-particles. GeoVax's vaccines are unique in expressing virus-like particles that display the trimeric membrane bound form of the HIV-1 envelope glycoprotein. In GeoVax's second-generation vaccine, the DNA prime co-expresses GM-CSF with the virus-like particles, delivering a normal human protein that stimulates immune responses to the site of vaccination. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV humoral (antibody) and cellular (cytotoxic T cell) immune responses, as well as the vaccines' safety.
AIDS is an epidemic that can affect anyone, regardless of race, gender, age or sexual orientation. 33 million people are currently infected globally and it is estimated that there will be 2.5 million new infections this year. Since the beginning of the epidemic, over a million people in the U.S. have contracted the virus. Every 9 1/2 minutes, someone in the U.S. is infected with AIDS. Globally, HIV is the top killer among women of reproductive age. HIV is a worldwide disease with different subtypes (or clades) of the virus predominating in different regions of the world. Clade B is the predominant subtype in North America. Globally, most infections involve subtypes AG, B and C. GeoVax vaccines are currently designed to function against clade B.
For more information, please visit .
Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: HVTN will commence, complete enrollment, and generate data regarding GeoVax vaccine clinical trials as and when expected, GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective, less costly, or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.
DGI
Investor Relations
Dillon Heins
or
Public Relations
Susan Forman/Laura Radocaj
(212) 825-3210
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 04.09.2012 - 07:00 Uhr
Sprache: Deutsch
News-ID 1147649
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
ATLANTA, GA
Phone:
Kategorie:
Dentistry
Anmerkungen:
Diese Pressemitteilung wurde bisher 185 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"GeoVax to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
"
steht unter der journalistisch-redaktionellen Verantwortung von
GeoVax Labs, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
